Kevin Guan

Kevin Guan is an associate in the firm’s Business Law Department and Life Sciences group. Mr. Guan has experience in mergers and acquisitions, venture capital, cross-border licensing, joint ventures, China inbound and outbound transactions, foreign direct investments and general corporate matters.  

Prior to joining Goodwin in 2021, Mr. Guan was most recently the in-house counsel at a tech startup in Hong Kong and previously practiced in the Shanghai office of a major U.S. law firm. Mr. Guan is a native Mandarin and Cantonese speaker and is fluent in English.

Mr. Guan’s experience includes representing:

M&A / VC Financing / Joint Venture

• AccuGen Group in its Series Seed Plus financing
• Allogene Therapeutics in its minority investment in Antion Biosciences
• Allogene Therapeutics in its joint venture with Overland Pharmaceuticals
• Ansys, Inc. in its acquisition of Zemax, LLC
• BridGene Biosciences in its Series A financing
• Exarta Therapeutics in its Series Seed financing
• HiFiBiO Therapeutics in its Series D financing
• HighTide Therapeutics in its Series C and Series C+ financing
• KBP Biosciences in its sale of Ocedurenone to Novo Nordisk
• Myro Therapeutics in its Series Seed financing
• Novo Holdings in its acquisition of Ritedose Corporation  
• OrbiMed in its joint venture with Kinnate Biopharma
• Proteologix Inc in its Series A financing
• Retex Pharmaceuticals in its Series Seed financing
• SK Biopharmaceuticals in its launch of Ignis Therapeutics, a biotech joint venture with 6 Dimensions Capital and other notable investors 
• VMS Investment Group in its investment in Harvest Integrated Research Organization
• Eight Roads Ventures in its venture capital investments in numerous China-based startups* 
• MedBanks in its Series B and Series C financing*
• Tongfu Microelectronics Co., Ltd. in its acquisition of Advanced Micro Devices, Inc.’s two semiconductor packaging factories in Asia*
• VcanBio Cell & Gene Engineering Corp., Ltd. in its acquisition of OriGene Technologies, Inc.*

Strategic Licensing and Collaboration Transactions

• Apollomics, Inc. in its licensing transaction with Edison Oncology
• Biotheus, Inc. in its exclusive global license and collaboration transaction with BioNTech for its PD-L1/VEGF bispecific antibody 
• Biotheus, Inc. in its research collaboration and licensing transaction with BioNTech for its two antibodies and VHH binders
• Biotheus, Inc. in its licensing and collaboration transaction with Hansoh for its EGCR/MET bispecific antibody
• DualityBio in its global strategic partnership transactions with BioNTech on three ADC programs
• HTDK Group in its collaboration transaction with Sofwave Medical
• Jemincare in its licensing transaction with Genentech for its novel oral androgen receptor degrader
• Leaderna Therapeutics Ltd in its licensing transaction with Lipigon Pharmaceuticals AB for Lipisense®
• Luye Pharma in its licensing transaction with BeiGene for its Goserelin Microspheres for Injection
• Neuro3 Therapeutics in its acquisition of the exclusive worldwide right to develop and commercialize clinical stage KCNQ2 from Lundbeck
• Novita Pharmaceuticals in its licensing transaction with China Resources Double-Crane for its fascin inhibitor
• Seagen Inc. in its licensing and collaboration transaction with Zai Lab for TIVDAK®
• Seagen Inc. in its licensing transaction with Nona Biosciences for Nona’s MSLN targeted ADC
• Shanghai Argo in its multiple-program RNAi Licenses and Strategic Collaborations with Novartis
• Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. in its licensing and collaboration transaction with Merck for seven pre-clinical ADC programs